The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight

Inclusion Criteria: * Age 18-65 years, * Diagnosed obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with comorbidities associated with excess body weight (including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease), * Eligibility for treatment with GLP-1 or GIP/GLP-1 analogues, * Not taking GLP-1 and GIP/GLP-1 analogue medications for at least one year prior to study enrollment, * Ability to provide informed consent, * Informed consent to participate in the study. Exclusion Criteria: * Age under 18 or over 65 years, * Inability to qualify for treatment with GLP-1 and GIP/GLP-1 analogues, * Pregnancy or breastfeeding, * Diagnosed eating disorders, * Active cancer or gastrointestinal conditions that may affect the absorption or tolerance of treatment (e.g., inflammatory bowel disease, conditions after extensive gastrointestinal resections, conditions after bariatric surgery), * Inability to participate in regular follow-up visits, * Inability to provide informed consent, * Failure to provide informed consent to participate in the study.